Keith T. Flaherty, MD

Keith is Director of Clinical Research at Massachusetts General Hospital Cancer Center, and a Professor of Medicine at Harvard Medical School.  He has authored or co-authored over 300 peer-reviewed primary research reports on seminal observations that have defined the the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in treating melanoma.  He serves as Editor-in-Chief of Clinical Cancer Research.

Keith is a leader in identifying and clinically evaluating de novo and acquired resistance to BRAF inhibitor therapy, work that has implications for the treatment of other malignant diseases.  He obtained his MD from Johns Hopkins University in 1997, after which he completed his internship and residency at Brigham and Women’s Hospital in Boston.  Keith then completed a fellowship in medical oncology at the Hospital of the University of Pennsylvania.  Prior to Mass General, he was an Assistant Professor of Medicine at the University of Pennsylvania School of Medicine and an Adjunct Professor at the Wistar Institute.